Search tips
Search criteria 


Logo of oncotargetLink to Publisher's site
Oncotarget. 2016 August 23; 7(34): 55924–55938.
Published online 2016 July 7. doi:  10.18632/oncotarget.10482
PMCID: PMC5342462

FGFR3-TACC3 fusion in solid tumors: mini review


Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the expanding therapeutic relevance of this pathway. Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR targeted therapies. FGFR gene aberrations and FGFR gene rearrangements are relatively rare in solid malignancies. The recently described FGFR3-TACC3 fusion protein has a constitutively active tyrosine kinase domain and promotes aneuploidy. We summarize the prevalence data on FGFR3-TACC3 fusions among different histological tumor types and the preliminary evidence that this rearrangement represents a targetable molecular aberration in some patients with solid tumors.

Keywords: FGFR3-TACC3 fusion, non-small cell lung cancer, phosphatidylinositol 3-Kinase (PI3K), aneuploidy, glioblastoma multiforme


The growing knowledge base of tumor genomics has led to never seen advances in the field of medical oncology. [1] The evolving molecularly targeted treatments of late-stage melanoma, gastro-intestinal stromal tumors, and non-small-cell lung cancer (NSCLC) exemplify these advances. [24]

The fibroblast growth factor receptor (FGFR) family consists of four subtypes of transmembrane tyrosine kinase receptors that play an important role in cell growth, differentiation and angiogenesis via binding of up to 22 known different FGF family ligands. [5] Upon FGFR activation through dimerization of receptor monomers and transphosphorylation of kinase domain loop tyrosine residues cytoplasmatic downstream molecules contribute to carcinogenic events mediated by PI3K/AKT, STAT and RAS/MAPK pathways (Figure (Figure1A).1A). [5, 6]

Figure 1
A. Fibroblast growth factor receptor (FGFR) has intra-cellular tyrosine kinase activity triggered by fibroblast growth factor (FGF) ligand. Its activation leads to FGFR transphosphorylation and activation of protein of ras oncogene (RAS)/mitogen-activated ...

Anomalous signaling through FGFR can occur through overexpression of receptors, activating mutations, gene amplification, or by FGFR-containing translocations in wide array of solid tumors as discussed below. Most importantly, these aberrations can represent important therapeutic targets in solid tumors and have supported the clinical development of several FGFR inhibitors and anti-FGFR drug conjugate (ADC) antibodies (Tables (Tables3,3, ,4,4, ,5,5, ,6,6, ,7,7, ,8,8, ,9).9). Herein we review the current literature and describe the cancer pathobiology, the prevalence, the pre-clinical, and the clinical data supporting drug development targeting the recently described FGFR3-TACC3 fusion.

Table 3
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies
Table 4
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued
Table 5
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued
Table 6
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued
Table 7
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued
Table 8
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued
Table 9
Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued


FGFR alterations relatively rare and were present in ~7% of a cohort of 4853 tumor samples including 47 different histological types. [7] When limiting to histologies with at least 75 samples analyzed, the frequencies of FGFR aberrations were higher among urothelial (31.7%), breast (17.4%), endometrial (11.3%), and endometrial/ovarian carcinomas (8.1%). [7] The majority of FGFR genomic alterations were FGFR amplifications and mutations (92%).

Evidence from early phase clinical trials support that FGFR aberrations can represent targetable events in solid tumors. In a phase I trial, twenty one patients with refractory squamous non-small cell lung cancer (sqNSCLC) harboring FGFR1-amplification were treated with the small molecule FGFR inhibitor BGJ398 (100 or 125 mg once daily in 28-day cycles). [8] Of 17 evaluable patients, 4 had radiologic tumor reduction and 3 had stable disease indicating that a subset of patients with FGFR pathway aberrations indeed benefits for FGFR targeted therapy. In another phase I trial BGJ398 also showed evidence of clinical activity in patients with solid tumors harboring FGFR aberrations, including 4 of 5 patients with urothelial cell carcinomas (4 of which originated in the bladder) with FGFR3-activating mutations. Additionally, two patients with FGFR1-amplified sqNSCLC achieved confirmed partial response. Tumor reductions were also observed in cholangiocarcinoma with an FGFR2 gene fusion, and FGFR1-amplified breast cancer. [9] In summary, given the rarity of FGFR aberrations the preliminary evidence of antitumor activity of FGFR targeted therapies comes from subpopulations of small early phase clinical trials. A small number of partial responses to FGFR targeted therapies have been documented among patients with sqNSCLC harboring FGFR1 amplification (BGJ398), cholangiocarcinoma harboring FGFR2 translocations (BGJ398), glioblastoma positive for FGFR3 translocation (JNJ-42756493), bladder cancer harboring FGFR3 mutations and translocations are sensitive to targeted therapies (JNJ-42756493 and BGJ398). [811]


Fusions have been described in the FGFR1-3 genes with multiple partners (i.e., TACC1, TACC2, TACC3, BAIAP2L1, BICC1, NPM1, PPAPDC1A, AFF3, SLC45A3 and AHCYL1) in a wide spectrum of tumors (i.e., cholangiocarcinoma, breast, and prostate cancer, sqNSCLC, gastric adenocarcinoma, colorectal adenocarcinoma, carcinoma of unknown primary and glioblastoma). [7, 1215]

Other rare FGFR fusions described included FGFR2-TACC3 (1), FGFR2-NPM1(3), FGFR2-TACC2(2), FGFR2-BICC1(2), FGFR2-C10orf68(1), FGFR3-JAKMIP1(1), FGFR2-KIAA1598(1), FGFR2-NCALD(1), FGFR2-NOL4(1), FGFR1-NTM(1), FGFR2-PPAPDCA(1), FGFR3-TNIP2(1), and FGFR3-WHSC1(1). Of note no FGFR4 gene fusion was observed in this large series. [7] Preliminary pre-clinical data support that these fusions represent important therapeutic targets. For instance stable cell lines harboring FGFR3-BAIAP2L1, FGFR3-TACC3, and FGFR2-CCDC6 fusions showed expression of active FGFR fusion kinases and activation of downstream mitogen-activated protein kinase ERK1/2 and the transcription factor STAT1. [12] The presence of FGFR fusions (FGFR3-BAIAP2L1) not only enhanced tumor cell proliferation, but also led to significant sensitivity to small kinase inhibitors (PD173074) in pre-clinical cellular and xenograft bladder cancer models, in contrast with FGFR3 mutant cell lines, which were not sensitive to kinase inhibition. [12] FGFR1-TACC1 fusion targeted therapy also showed anti-tumor effects in pre-clinical GBM model. [13] Cholangiocarcinoma mice model harboring FGFR2-AHCYL1, FGFR2-CCDC6, and FGFR2-BICC1 was sensitive to treatment with FGFR kinase inhibitors BGJ398 and PD173074. [16, 17]

TACC3 gene has been identified as an important partner of these FGFR fusions and associated with the pathogenesis of several solid tumors. [1820] TACC3 (transforming acidic coiled-coil containing protein 3) belongs to the TACC gene family, which also includes TACC1 and TACC2. TACC3 protein has a coiled-coil domain at the C terminus, known as the TACC domain, which promotes stability and organization of mitotic spindle. [21]

FGFR3-TACC3 fusions were first described in glioblastoma multiforme (GBM) and bladder urothelial tumors. [13, 15] Subsequent manuscripts underscored the low frequency of FGFR3-TACC3 gene fusions across different tumor types.

Among the 4853 tumors samples analyzed by Helsten et al. only 28 exhibited FGFR gene fusions, and 14 samples had FGFR3-TACC3 fusions. Accompanying genomic aberrations observed primarily affected TP53 tumor suppressor gene, AKT/mTOR/PTEN pathway and cell cycle control genes (i.e., CNNE1, CDK2 and 4) (Table (Table1).1). [7]

Table 1
Co-existing genomic aberrations among 14 FGFR3-TACC3 fusion cases.[7]

FGFR3-TACC3 fusions are formed by rare intrachromosomal rearrangements located within 150 kb of the FGFR3 gene on chromosome 4p16 (Figure (Figure2).2). [13] It has been proposed that the fusion, which occurs via a tandem duplication event, leads to loss of an miR-99a binding site within the 3′-untranslated region (3′- UTR) of FGFR3, releasing FGFR3 signaling from miR-99a-dependent inhibition and enhancing tumor progression relative to wild type FGFR3. [22] Given the close proximity of the FGFR3 and TACC3 genes, identification of the fusion by FISH is technically challenging. [23] Therefore the most common methods have involved transcriptomic analysis by RNA-seq and RT-PCR in addition to whole-genome sequencing. [7, 13, 23] Di Stefano et al. have also utilized immunostaining of the N terminus of FGFR3 and found uniform overexpression of FGFR3 in a subset of glioblastoma multiforme (GBM) cases with FGRF3-TACC fusions that were identified by RT-PCR. [23] Those findings demonstrate that detection of FGFR3 amplification by IHC or IF may serve as a method to screen for FGRF3-TACC fusions which is clinically relevant since RNA sequencing is not common practice. [24] The fusion protein exhibits constitutive kinase activity, induces mitotic, chromosomal segregation defects and triggers aneuploidy (Figure (Figure1B).1B). [13] The presence of the TACC coiled-coil domain increases the activity of FGFR3 through more promiscuous constitutive phosphorylation of tyrosine kinase residues within the FGFR3 protein, and preferential MAPK kinase activation (Figure (Figure1A).1A). [25] Moreover, preclinical and clinical results have shown that FGFR inhibitors can block the tyrosine kinase activity of this fusion protein.

Figure 2
FGFR3-TACC3 gene fusion

Treatment of nasopharyngeal carcinoma cells carrying the FGFR3-TACC3 fusion with FGFR inhibitor PD173074 inhibited cell proliferation. [26] RT4 urothelial carcinoma line harboring FGFR3-TACC3 fusion also exhibited sensitivity to this same FGFR inhibitor in a xenograft model. [12] Similar results were seen in GBM in vivo and in vitro models carrying the FGFR3-TACC3 fusions, which was not only associated oncogenic transformation but also exhibited significant sensitivity to FGFR inhibitor JNJ-42756493. [13, 22, 23]

The clinical relevance of FGFR3-TACC3 has been underscored by preliminary results from clinical studies and case reports of tumor responses to the treatment with FGFR inhibitors. For instance, the phase I trial with FGFR inhibitor JNJ-42756493 including 65 patients with advanced solid tumors included 4 patients with FGFR3-TACC3 translocation. [10] Three partial responses (two confirmed and one unconfirmed) were seen among 3 patients with urothelial, two of which cancer harbored FGFR3-TACC3 fusion. One of these patients stayed on treatment for about 10 months. Another confirmed partial response was observed in a patient with glioblastoma with FGFR3-TACC3. Tumor shrinkage was also seen in a patient with adrenal carcinoma with FGFR3-TACC3/FGFR2- CCDC6 (FGFR3-TACC3 being the predominant translocation), who received treatment for 10 months before disease progression. In agreement with preclinical results, these results suggest that FGFR3-TACC3 fusion is indeed an actionable therapeutic target.



The first report of this fusion emerged from a small subset of patients with GBM with 2 out of 97 samples harboring FGFR3-TACC3. [13] A subsequent study with 795 cases of gliomas (584 GBMs and 211 grade II-III gliomas) described 17 cases (2.9%) of FGFR3-TACC3 genomic fusions among the GBM group, and 3 cases among lower grade gliomas. [23] Amplicons ranged from 928 bp (for FGFR3exon18-TACC3exon13) to 1,706 bp (for FGFR3ex18-TACC3ex4). All tested FGFR3-TACC3 positive tumors showed strong expression of FGFR3 by tumor cells on immunohistochemistry (IHC). Epidermal growth factor receptor gene (EGFR) amplification showed significant negative correlation with FGFR3-TACC3 status; CDK4 and MDM2 amplification had significant positive correlation with FGFR3-TACC3 (CDK4 amplification was seen in 7/16 FGFR3-TACC3 positive cases). No statistically significant correlation was seen between FGFR3-TACC3 fusions and other genetic and epigenetic alterations (CDKN2A deletion, TERT promoter mutations, gain of chromosome 7p, loss of chromosome 10q, and methylation of the MGMT promoter). Parker et al. also reported higher frequency of FGFR3-TACC3 fusions in GBMs when compared to gliomas. [22] Four out of 48 (8.3%) GBMs tested were positive for this fusion, whereas none of the 43 low-grade glioma samples showed this translocation. In addition, 2 out 157 GBM (1.2%) and 2 out of 461 low grade gliomas (0.4%) samples from The Cancer Genome Atlas (TCGA) dataset tested positive for FGFR3-TACC3 fusions which reinforced the notion that this fusion is more common in high grade gliomas. [14] In another series 3 out of 59 patients with primary GBM harbored this fusion gene. [27] Wu et al. reported 2 cases of GBM harboring FGFR3-TACC3 fusion from the TGCA database. [12] In summary, it is estimated that 1.2-8.3% of GBMs will carry this translocation.

Urothelial cancer

The TCGA project reported a comprehensive genomic analysis of 131 high-grade muscle invasive urothelial bladder carcinomas including gene fusions. Three cases of tumors with FGFR3-TACC3 fusion were reported (~2.3%). The breakpoints were in intron 10 of TACC3 and intron 16 (2 cases) or exon 17 (1 case) of FGFR3. [28] Two cases among 99 samples analyzed showed two distinct FGFR3-TACC3 genomic fusions; first, intron 17 of FGFR3 with intron 10 of TACC3 resulting in exon 17 of FGFR3 being spliced 5′ to exon 11 of TACC3 in the fuse mRNA; second, intron 17 of FGFR3 with exon 4 of TACC3 at the gene level and in the fused mRNA, exon 17 and fragment of intron 17 in FGFR3, and fragment of exon 4 in TACC3 were merged into a novel exon. [29] Analysis of 250 samples of bladder urothelial carcinoma by RNA-seq detected FGFR3-TACC3 in 5 specimens (2%). [14] Helsten et al. described 126 cases of urothelial carcinomas and 4 cases (3%) of FGFR3-TACC3 translocations were observed. [7] Williams et al. reported results of analysis of 2 tumor samples positive for FGFR3 exon 18 and TACC3 exon 13 fusions among 32 selected bladder carcinoma samples. [15] Taken together, a total of 14 cases of urothelial carcinoma carrying FGFR3-TACC3 translocation have been described with an estimated incidence of 2.6% among the 539 cases described above.

Non-small cell lung cancer

RNA sequencing of 492 sqNSCLC from the TCGA showed only 3 cases of FGFR3-TACC3 fusions; none of 513 cases of adenocarcinomas harbored this translocation. [14] Another study describing genomic analysis of 675 cases of NSCLC showed only one case of FGFR3-TACC3 fusion (breakpoint not specified), this was associated with existing CDKN2A-loss and MDM2 amplification. [7] Wu et al. reported through analysis of the TGCA dataset 4 cases of sqNSCLC harboring FGFR3-TACC3 fusion. [12] Capelletti et al. identified 3 out 576 patients with adenocarcinoma of the lung harboring FGFR3-TACC3. [30] Fusion variants identified included exon 17 FGFR3 to exon exon 8 of TACC3; exon 17 of FGFR3 and exon 11 of TACC3; and exon 17 of FGFR3 to exon 4 TACC3 resulting in an overall prevalence of 0.5%. An additional analysis of 1,328 NSCLC samples revealed 15 FGFR3-TACC3 fusion variants identified through RT-PCR [31]. Histological distribution was as follows: 6/1016 (0.6%) adenocarcinomas and 9/312 (2.9%) squamous cell carcinoma of the lung suggesting the FGFR3-TACC3 fusions are more frequent in sqNSCLC. FGFR3-TACC3 fusion correlated with positive smoking history and male gender in univariate analysis. Tumor size > 3cm correlated with FGFR3 fusions independently in multivariate modeling. FGFR3-TACC3 fusions were distributed as follows: E18:E11 2 cases, E17:E11 9 cases, E17:E8 1 case, E17:E5 1 case, and E17:E10 2 cases.

Another cohort of patients from Korea was analyzed and only 2 cases of FGFR3-TACC3 fusion were detected (E17:E8 and E18:E9). The same author reviewed the samples of the TCGA database and found 4 out of 178 samples positive for this fusion. [32] Two more cases of FGFR3 E18 fused with TACC3 E10 were reported in sqNSCLC. [33] The TCGA dataset reported genomic analysis through RT-PCR of 230 previously untreated adenocarcinomas of the lung and 178 previously untreated sqNSCLC; FGFR fusions were not reported in either series. [34, 35] In summary, FGFR3-TACC3 fusions are rare in NSCLC but seem to be more common in sqNSCLC histological type with an estimated prevalence consistently lower than 2.9%.

Cervical cancer

Three cases of TACC3-FGFR3 translocations break points in patients with advanced cervical carcinoma have been described with early evidence of clinical benefit from FGFR targeted treatment. [36] One of the cases was a metastatic recurrent to the lung adenosquamous carcinoma of the cervix. The metastatic tumor showed FGFR3-TACC3 fusion (break point intron 17 and TACC3 intron 10). Associated genomic aberrations were: AKT1 missense mutation, mTOR point mutation, ATRX truncating nonsense mutation. The patient was treated with FGFR targeted therapy achieving stable disease for 4 cycles. In the second case, the patient had well differentiated squamous cell carcinoma of the cervix stage. Tumor tissue from the original biopsy showed FGFR3-TACC3 fusion (break points FGFR3 intron 18 and TACC3 intron 7) as well as BRAF 3′ tandem duplication, activating PIK3CA missense mutation, CDNK2A loss, and activating missense mutations in KRAS and HRAS. The third case was a squamous cell carcinoma of the cervix in which the following genomic aberrations were identified on hysterectomy specimen: FGFR3-TACC3 fusion (breakpoints at FGFR3 intron 17 and TACC intron 10) and partial loss of STK11, and RB1 loss.

Xiang et al. performed transcriptomic (RNA) followed by cDNA analysis of 285 cases of early stage carcinoma of the cervix; 11 cases of FGFR3-TACC3 translocations were described (3.9%) with 4 variants [FGFR3 (1_758) fused with TACC3 (549_838), FGFR3(1_758) fused with TACC3(648_838), FGFR3 (1_758) fused with TACC3 (648_838), and the most frequent variant FGFR3 (1_768) fused with TACC3(538_838)] [37]. There were four cases of squamous cell carcinoma, 3 cases of adenocarcinoma 3 cases of adenosquamous, and 1 small cell carcinoma. Other sporadic cases of FGFR3-TACC3 translocation in cervical carcinoma have been reported as part of genomic aberrations analysis of solid tumors: FGFR3-TACC3 fusion (intron 17-intron 7) one case of cervical carcinoma. [7]

Head and neck cancer

Among 411 head and neck SCC tumor samples analyzed using RNA sequencing data through the TGCA only 2 harbored FGFR3-TACC3 fusion. [14] Wu et al. reported two additional cases of head and neck cancer harboring this fusion. [12] An additional analysis of 279 head and neck SCC tumor samples from the TGCA dataset (172 oral cavity, 33 oropharynx, 72 laryngeal tumors) and cases of FGFR3-TACC3 were appreciated in two of the HPV+ samples. [38]

Gastrointestinal malignancies

FGFR3-TACC3 fusions are rare event as illustrated by analysis RNA sequencing of 856 tumor samples [hepatocellular carcinoma (194), colon (286), rectum (91), and gastric adenocarcinomas (285)] ; in which no tumor showed this translocation. [14]

Other malignancies

Two studies analyzed a total of 1594 cases of breast cancer no FGFR3-TACC3 fusion was reported. [7, 14] Single cases of carcinoma of unknown primary, endometrial carcinoma, renal cell carcinoma, gallbladder, papillary kidney tumor, and prostate adenocarcinoma harboring the FGFR3-TACC3 fusion have been described. [7, 14]


In the recent years the field of medical oncology has witnessed unprecedented advances in the understanding of cancer biology. FGF/FGFR pathway is a thriving area of targeted drug development in a wide array of tumors (Tables (Tables3,3, ,4,4, ,5,5, ,6,6, ,7,7, ,8,8, ,9).9). FGFR3-TACC3 was first described in 2012 in two patients with GBM. [13] Since then FGFR3-TACC3 fusion has been reported in numerous solid tumors including urothelial carcinoma, NSCLC, thyroid, and cervical carcinoma (Table (Table2).2). [12] In addition dataset analysis through bioinformatics, namely the TCGA dataset, yield other rarer instances in which this aberration can be found such as prostate cancer, head and neck cancer, and kidney papillary cancer. [14]

Table 2
Cross-sectional studies and case series reporting positive FGFR3-TACC3 fusions (excluding TCGA dataset samples)

The clinical relevance of FGFR3-TACC3 has been highlighted by 3 out of 4 partial responses among patients with tumors harboring FGFR3-TACC3 fusions treated with FGFR inhibitor JNJ-42756493. [10] In agreement with preclinical results, these results suggest that FGFR3-TACC3 fusion is indeed an actionable therapeutic target. Furthermore taking into account the obvious limitation of the sparse clinical data thus far tumors harboring FGFR3-TACC3 fusions seem to be more sensitive FGFR targeted therapies when compared to other FGFR aberrations. This is particularly important, as there are limited treatment options for patients with aggressive tumors in which FGFR3-TACC3 fusions have been described such as GBM and bladder cancer. Future studies should take into account that FGFR3-TACC3 fusion has shown positive correlations with PI3K/AKT/mTOR pathway, cell cycle control (CDK4, CDK2, and CCND1), and MDM2 aberrations (Table (Table1).1). [23, 36, 39] The corollary to these concomitant findings is that one could hypothesize that the combined approach targeting FGFR3-TACC3 and its downstream oncogenic proteins may further enhance the efficacy of FGFR aberrant targeted therapy. Notwithstanding its rarity, FGFR3-TACC3 fusions are present in wide array of solid tumor types and its analysis should be an integral part of screening procedures in FGFR targeted trials in solid tumors.

Elucidation of the potential interaction between FGFR and its fusions with the immune system is also warranted. Pre-clinical data suggest that FGFR3 mutations are exclusive to non-inflamed bladder cancers (~ 30% of tumors), a subgroup characterized by absence of CD8 tumor infiltrating lymphocytes (CD8 TILs), worsen prognosis, and lower chance of responding to PD-L1 blockade. [4042] The exclusion of CD8 TILs from the tumor microenvironment limits the benefit from immunotherapies in melanoma and might carry similar relevance to bladder cancer. [42] Nevertheless, these preliminary results highlight a possible link between FGFR pathway aberrations and immune modulation of tumor microenvironment that could be explored therapeutically.



There is no conflict of interest.


1. Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ. Is Personalized Medicine Here? Oncology (Williston Park) 2016;30:293–303. 307. [PubMed]
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364:2507–2516. [PMC free article] [PubMed]
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine. 2010;362:2380–2388. [PubMed]
4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England journal of medicine. 2002;347:472–480. [PubMed]
5. Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR Signaling in Cancer. Clin Cancer Res. 2015;21:2684–2694. [PubMed]
6. Gallo LH, Nelson KN, Meyer AN, Donoghue DJ. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 2015;26:425–449. [PubMed]
7. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016;22:259–67. [PubMed]
8. Nogova L, Cassier PA, Hidalgo M, Delord JP, Schuler MH, Lim WT, Camidge DR, Buettner R, Heukamp LC, Gardizi M, Scheffler S, Kambartel K, Ringeisen FP, Sen S, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol. 2014;32:5. [PubMed]
9. Lecia V, Sequist PC, Varga V, Tabernero J, Schellens JH, Delord JP, LoRusso P, Camidge DR, Medina MH, Schuler M, Campone M, Tian GG, Wong S, Corral J, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA Philadelphia (PA): AACR. Cancer Res 2014;74:Abstract nr CT326. [Cross Ref]
10. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2015;33:3401–3408. [PubMed]
11. Milind M, Javle RTS, Zhu A, Sadeghi S, Choo SP, Borad MJ, Lowery MA, El-Khoueiry A, Macarulla T, Philip PA, Oh DY, Van Cutsem E, Yeh KH, Isaacs R, McGarry C, Sen S, Bekaii-Saab TS. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol. 2016;34
12. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer discovery. 2013;3:636–647. [PMC free article] [PubMed]
13. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (New York, NY) 2012;337:1231–1235. [PMC free article] [PubMed]
14. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nature communications. 2014;5:4846. [PMC free article] [PubMed]
15. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Human molecular genetics. 2013;22:795–803. [PMC free article] [PubMed]
16. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge T, Shibata T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–1434. [PubMed]
17. Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, et al. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer letters. 2016 [PubMed]
18. Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q, Wen ZS. High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget. 2015;6:6850–6861. doi: 10.18632/oncotarget.3190. [PMC free article] [PubMed] [Cross Ref]
19. Ha GH, Kim JL, Breuer EK. TACC3 is essential for EGF-mediated EMT in cervical cancer. PloS one. 2013;8:e70353. [PMC free article] [PubMed]
20. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, Still IH. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005;5:8. [PMC free article] [PubMed]
21. Hood FE, Royle SJ. Pulling it together: The mitotic function of TACC3. Bioarchitecture. 2011;1:105–109. [PMC free article] [PubMed]
22. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. The Journal of clinical investigation. 2013;123:855–865. [PMC free article] [PubMed]
23. Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, et al. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res. 2015;21:3307–3317. [PMC free article] [PubMed]
24. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016;17:257–271. [PubMed]
25. Nelson KN, Meyer AN, Siari A, Campos AR, Motamedchaboki K, Donoghue DJ. Oncogenic Gene Fusion FGFR3-TACC3 is Regulated by Tyrosine Phosphorylation. Mol Cancer Res. 2016;14:458–69. [PubMed]
26. Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer biology & therapy. 2014;15:1613–1621. [PMC free article] [PubMed]
27. Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, Hu BQ, Yan W, Zhang W, Akers J, Ramakrishnan V, Li J, Carter B, Liu YW, Hu HM, Wang Z, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome research. 2014;24:1765–1773. [PubMed]
28. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322. [PMC free article] [PubMed]
29. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, Ye R, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature genetics. 2013;45:1459–1463. [PubMed]
30. Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Janne PA. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014;20:6551–6558. [PubMed]
31. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014;20:4107–4114. [PubMed]
32. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32:121–128. [PMC free article] [PubMed]
33. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. The Journal of pathology. 2013;230:270–276. [PubMed]
34. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550. [PMC free article] [PubMed]
35. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525. [PMC free article] [PubMed]
36. Carneiro BA, Elvin JA, Kamath SD, Ali SM, Paintal AS, Restrepo A, Berry E, Giles FJ, Johnson ML. FGFR3-TACC3: A novel gene fusion in cervical cancer. Gynecologic oncology reports. 2015;13:53–56. [PMC free article] [PubMed]
37. Xiang L, Li J, Jiang W, Shen X, Yang W, Wu X, Yang H. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget. 2015;6:4968–4975. doi: 10.18632/oncotarget.3212. [PMC free article] [PubMed] [Cross Ref]
38. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582. [PMC free article] [PubMed]
39. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell cycle (Georgetown, Tex) 2015;14:2121–2128. [PMC free article] [PubMed]
40. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:3967–3972. [PubMed]
41. Sweis RF SS, Gajewski T. Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. J Clin Oncol. 2015;33 abstract 4511.
42. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–235. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC